Awale, Guleid
Kan, Ho-Man
Laurencin, Cato T.
Lo, Kevin W.-H.
Funding for this research was provided by:
Division of Chemical, Bioengineering, Environmental, and Transport Systems (1332329)
Article History
Received: 30 June 2022
Revised: 31 October 2022
Accepted: 4 November 2022
First Online: 17 November 2022
Declarations
:
: Dr. Cato T. Laurencin is the editor-in-chief and Dr. Kevin Lo is the assistant managing editor of Regenerative Engineering and Translational Medicine. Dr. Cato T. Laurencin has the following competing financial interests: Mimedx, Alkermes Company, Biobind, Soft Tissue Regeneration/Biorez, and Healing Orthopaedic Technologies-Bone. The authors have no non-financial competing interests.